IMA402 (Phase Ia) clinical trials

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

This study is testing a new medicine, IMA402, for adults with advanced or returning solid cancers that haven't responded to other treatments. We want to see if it's safe, what dose works best, and if it can help shrink tumours.